Package Leaflet: Information for the User
Apidra100Units/ml solution for injection in a vial
Insulin glulisine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Apidra is an antidiabetic agent used to reduce high blood sugar levels in patients with diabetes mellitus. It can be administered to adults, adolescents, and children from 6 years of age. Diabetes mellitus is a disease in which your body does not produce enough insulin to control blood sugar levels.
It is produced by biotechnology. It has a rapid onset of action between 10-20 minutes and a short duration of action, around 4 hours.
Do not use Apidra
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting Apidra.
Follow carefully the instructions for dosing, monitoring (blood tests), diet, and physical activity (physical work and exercise) as indicated by your doctor.
Special patient groups
If you have liver or kidney problems, consult your doctor as you may need a lower dose.
There is no clinical information available on the use of Apidra in children under 6 years of age.
Skin changes at the injection site
The injection site should be rotated to avoid skin changes, such as lumps under the skin. Insulin may not work as well if injected into a swollen area (see How to use Apidra). Contact your doctor if you are currently injecting into a swollen area before starting to inject into a different area. Your doctor may advise you to check your blood sugar levels more closely and adjust your insulin or other antidiabetic medications.
Travel
Before traveling, consult your doctor. You may need to discuss:
Illness and injury
Your diabetes management may require special care in the following situations:
In most cases, you will need a doctor. Make sure to consult a doctor immediately.
If you have type 1 diabetes (insulin-dependent diabetes mellitus), do not stop taking your insulin and follow a proper diet. Always inform the people in charge of your care or treatment that you need insulin.
Some patients with long-standing type 2 diabetes mellitus and previous heart disease or stroke who were treated with pioglitazone and insulin developed heart failure. Inform your doctor as soon as possible if you experience symptoms of heart failure such as unusual shortness of breath or rapid weight gain or localized swelling (edema).
Using Apidra with other medicines
Some medicines produce changes in blood sugar levels (an increase, a decrease, or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are too low or too high. Be careful when starting to take another medicine and also when stopping it.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Ask your doctor before taking a medicine if it can affect your blood sugar level and what measures you should take, if any.
Among the medicines that may cause a decrease in your blood sugar level (hypoglycemia) are:
Among the medicines that may cause an increase in your blood sugar level (hyperglycemia) are:
Your blood sugar level may rise or fall if you take:
Pentamidine (used to treat some parasitic infections) may cause hypoglycemia, which can sometimes be followed by hyperglycemia.
Beta-blockers, like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine), may mask or completely suppress the early warning symptoms that could help you recognize hypoglycemia.
If you are unsure whether you are taking any of these medicines, ask your doctor or pharmacist.
Using Apidra with alcohol
Your blood sugar levels may rise or fall if you drink alcohol.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Tell your doctor if you are planning to become pregnant or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes and prevention of hypoglycemia are important for the health of your baby.
There are limited or no data on the use of Apidra in pregnant women.
If you are breastfeeding, consult your doctor as you may need to adjust your insulin doses and diet.
Driving and using machines
Your ability to concentrate or react may be reduced if:
Be aware of this possible problem, considering all situations that may pose a risk to you or others (such as driving a vehicle or using machines).
You should ask your doctor for advice on your ability to drive if:
Important information about some of the ingredients of Apidra
This medicine contains less than 1 mmol (23 mg) of sodium per dose, i.e., it is essentially "sodium-free".
Apidra contains metacresol
Apidra contains metacresol, which may cause allergic reactions.
Dose
Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
Your doctor will determine the dose of Apidra you need based on your lifestyle and the results of your blood sugar (glucose) tests and previous insulin treatment.
Apidra is a short-acting insulin. Your doctor may advise you to use it in combination with an intermediate-acting, long-acting, or basal insulin, or with tablets used to treat high blood sugar levels.
If you switch from another insulin to insulin glulisine, your dose may need to be adjusted by your doctor.
Many factors can influence your blood sugar level. You should know these factors so that you can react correctly to changes in your blood sugar level and avoid it becoming too high or too low. See the box at the end of the leaflet for more information.
Method of administration
Apidra is injected under the skin (subcutaneously). It can also be administered intravenously by healthcare professionals under strict medical supervision.
Your doctor will show you which area of the skin to inject Apidra into. Apidra can be injected into the abdominal wall, thigh, or upper arm, or by continuous infusion into the abdominal wall. The effect will be slightly faster if the insulin is injected into your abdomen. As with other insulins, the injection and infusion sites within an injection area (abdomen, thigh, or upper arm) should be rotated from one injection to another.
Frequency of administration
Apidra should be administered shortly (0-15 minutes) before or shortly after meals.
Instructions for correct use
How to handle the vials
Apidra vials are used with insulin syringes with a graduated scale and with an insulin pump system.
Inspect the vial before use. It should only be used if the solution is clear, colorless, and has no visible particles.
Do not shake or mix before use.
Always use a new vial if you notice that your blood sugar control is worsening unexpectedly. This is because the insulin may have lost some of its effectiveness. If you think you may have a problem with Apidra, have it checked by your doctor or pharmacist.
If you need to mix two types of insulin |
Apidra should not be mixed with any other insulin preparation other than human insulin NPH.
If Apidra is mixed with human insulin NPH, Apidra should be drawn into the syringe first. The injection should be performed immediately after mixing.
How to handle the infusion pump system |
Before using Apidra in a pump system, you should have received detailed instructions on how to use the pump system. You should also have been informed about what to do if you become ill or if your blood sugar levels become too high or too low, or if the pump system fails.
Use the pump system recommended by your doctor. Read and follow the instructions that come with your insulin infusion pump. Follow your doctor's instructions regarding basal infusion rate and insulin bolus administration at mealtime. Check your blood sugar level regularly to ensure you are getting the benefit of insulin infusion and that the pump is working properly.
Change the infusion set and reservoir at least every 48 hours using an aseptic technique. These instructions may differ from the instructions that come with your insulin infusion pump. When using Apidra in the pump system, it is important to always follow these specific instructions. Not following these specific instructions can lead to serious adverse reactions.
Apidra should never be mixed with diluents or any other insulin when used in a pump.
What to do if the pump system fails or when the pump is not used correctly |
Problems with the pump or infusion set or incorrect use of the pump can result in you not getting enough insulin. This can cause your blood sugar level to rise rapidly and lead to diabetic ketoacidosis (buildup of acid in the blood because your body is breaking down fat instead of sugar).
If your blood sugar level starts to rise, contact your doctor, pharmacist, or nurse as soon as possible. They will inform you what to do.
You may need to use Apidra with syringes or pens. You should always have an alternative insulin delivery system available for subcutaneous injection in case the pump system fails.
If you use more Apidra than you should
If you forget to use Apidra
If you stop using Apidra
This could lead to severe hyperglycemia (very high blood sugar levels) and ketoacidosis (buildup of acid in the blood because your body is breaking down fat instead of sugar). Do not stop your treatment with Apidra without consulting your doctor; they will tell you what to do.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Mix-ups between insulins
You should always check the insulin label before each injection to avoid mix-ups between Apidra and other insulins.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Severe Adverse Effects
Hypoglycemia (low blood sugar levels) can be very severe.Hypoglycemia is a very frequently observed adverse effect (it can affect more than 1 in 10 patients).
Hypoglycemia (low blood sugar levels)means that you do not have enough sugar in your blood.If your blood sugar level drops too low, you may lose consciousness. Severe hypoglycemia can cause brain damage and can be life-threatening. If you experience symptoms of low blood sugar, act immediatelyto raise your blood sugar level. See the box at the end of this leaflet, where you will find more important information about hypoglycemia and its treatment.
If you experience the following symptoms, contact your doctor immediately:
Systemic allergic reactionsare adverse effects that are rarely observed (they can affect up to 1 in 100 patients).
Generalized allergy to insulin:related symptoms may include large-scale skin reactions (skin rash and itching all over the body), severe swelling of the skin or mucous membranes (angioedema), difficulty breathing, decreased blood pressure with rapid heartbeat and sweating. These can be symptoms of severe generalized allergy to insulin, including anaphylactic reaction that can be life-threatening.
Hyperglycemia (high blood sugar levels) means that there is too much sugar in the blood.
The frequency of hyperglycemia cannot be estimated. If your blood sugar level is too high, this indicates that you may need more insulin than you have injected.
Hyperglycemia can cause diabetic ketoacidosis (increase in acid in the blood due to the body breaking down fat instead of sugar).
These are severe adverse effects.
These conditions can occur when there are problems with the infusion pump or when the pump system is not used correctly.
This means that you may not always be able to get enough insulin to treat your diabetes.
If this happens, you should seek urgent medical help.
You should always have an alternative insulin administration system for subcutaneous injection(see section 3 "How to handle the infusion pump system" and "What to do if the pump system fails or when the pump is not used correctly". For more information on the signs and symptoms of hyperglycemia, see the box at the end of this leaflet.
Other Adverse Effects
If insulin is injected too frequently in the same place, the fatty tissue can shrink (lipoatrophy) or become thicker (lipohypertrophy) (can affect up to 1 in 1,000 people). Lumps under the skin can also occur due to the accumulation of a protein called amyloid (cutaneous amyloidosis; the frequency of this is unknown). Insulin may not work very well if injected into a lumpy area. Change the injection site to help avoid these skin changes.
Frequent Adverse Effects(can affect up to 1 in 10 patients)
Reactions at the injection site (such as redness, intense pain, itching, hives, swelling, or inflammation) can be experienced. These reactions can also spread around the injection site. Most minor insulin reactions usually resolve on their own in a few days or weeks.
Adverse Effectswhose frequency cannot be estimated from the available data
A significant change (improvement or worsening) in the control of your blood sugar level can temporarily worsen your vision. If you have proliferative retinopathy (an eye disease related to diabetes), severe hypoglycemic attacks can cause temporary loss of vision.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and on the label of the vial after CAD/EXP. The expiration date is the last day of the month indicated.
Unopened vials
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Do not place Apidra near the freezer compartment or next to a cold accumulator.
Keep the vial in the outer packaging to protect it from light.
Opened vials
Once in use, the vial can be stored for a maximum of 4 weeks in the outer packaging below 25°C, protected from direct heat or direct light. Do not use the vial after this period.
It is recommended to note the date of the first use on the label.
Do not use this medicine if it is not colorless and transparent.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Composition of Apidra
Appearance of the Product and Container Contents
Apidra 100 Units/ml injectable solution in a vial is a clear, colorless, aqueous solution without visible particles.
Each vial contains 10 ml of solution (1000 Units). There are packs of 1, 2, 4, and 5 vials of 10 ml.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Sanofi-Aventis Deutschland GmbH
D-65926 Frankfurt am Main
Germany
Manufacturer:
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst, D-65926 Frankfurt
Germany
You can request more information about this medicinal product by contacting the local representative of the Marketing Authorization Holder:
Belgium Sanofi Belgium Tel: +32 (0)2 710 54 00 | Luxembourg Sanofi Belgium Tel: +32 (0)2 710 54 00 (Belgium) |
Bulgaria SANOFI BULGARIA EOOD Tel: +359 (0)2 970 53 00 | Hungary SANOFI-AVENTIS Zrt. Tel: +36 1 505 0050 |
Czech Republic sanofi-aventis, s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.p.A. Tel: +39 02 39394275 |
Denmark Sanofi A/S Tel: +45 45 16 70 00 | Netherlands sanofi-aventis Netherlands B.V. Tel: +31 20 245 4000 |
Germany Sanofi-Aventis Deutschland GmbH Tel: 0800 52 52 010 Tel from abroad: +49 69 305 21 131 | Norway sanofi-aventis Norge AS Tel: +47 67 10 71 00 |
Estonia sanofi-aventis Estonia OÜ Tel: +372 627 34 88 | Austria sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
Greece sanofi-aventis AEBE Tel: +30 210 900 16 00 | Poland sanofi-aventis Sp. z o.o. Tel: +48 22 280 00 00 |
Spain sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi - Produtos Farmacêuticos, Lda. Tel: +351 21 35 89 400 |
France sanofi-aventis France Tel: 0 800 222 555 Call from abroad: +33 1 57 63 23 23 | Romania Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Croatia sanofi-aventis Croatia d.o.o. Tel: +385 1 600 34 00 Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenia sanofi-aventis d.o.o. Tel: +386 1 560 48 00 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia sanofi-aventis Pharma Slovakia s.r.o. Tel: +421 2 33 100 100 |
Italy Sanofi S.p.A. Tel: 800 13 12 12 (technical questions) 800 536389 (other questions) | Finland Sanofi Oy Tel: +358 (0) 201 200 300 |
Cyprus sanofi-aventis Cyprus Ltd. Tel: +357 22 871600 | Sweden Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvia sanofi-aventis Latvia SIA Tel: +371 67 33 24 51 | United Kingdom Sanofi Tel: +44 (0) 845 372 7101 |
Lithuania UAB “SANOFI-AVENTIS LIETUVA” Tel: +370 5 2755224 |
Date of Last Revision of this Leaflet:
Other Source of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/
HYPERGLYCEMIA AND HYPOGLYCEMIA
Always carry some sugar with you (at least 20 grams).
Always carry information that indicates you are a person with diabetes.
HYPERGLYCEMIA (high blood sugar levels)
If you have very high blood sugar levels (hyperglycemia), you may not have injected enough insulin.
Why does hyperglycemia occur?
Some examples are:
Warning signs of hyperglycemia
Thirst, increased need to urinate, fatigue, dry skin, redness of the face, loss of appetite, low blood pressure, rapid heartbeat, and the presence of glucose and ketone bodies in the urine. Abdominal pain, deep and rapid breathing, drowsiness, or even loss of consciousness may be signs of a serious condition (ketoacidosis) due to lack of insulin.
What to do in case of hyperglycemia?
You should check your blood sugar level and your urine acetone level as soon as any of the above symptoms occur. Severe hyperglycemia or ketoacidosis should always be treated by a doctor, usually in a hospital.
HYPOGLYCEMIA (low blood sugar levels)
If your blood sugar level drops too low, you may lose consciousness. Severe hypoglycemia can cause a heart attack or brain damage and can be life-threatening. You should normally be able to recognize when your blood sugar level is dropping too low to take the necessary measures.
Why does hypoglycemia occur?
Some examples are:
It is also more likely to occur if:
Warning signs of hypoglycemia
Examples of symptoms that indicate your blood sugar level is dropping too low or too quickly: sweating, moist and sticky skin, anxiety, rapid heartbeat, high blood pressure, palpitations, and irregular heartbeat. These symptoms often occur before symptoms of low blood sugar in the brain.
Examples of symptoms that indicate low blood sugar in the brain: headaches, intense hunger, nausea, vomiting, fatigue, drowsiness, sleep disturbances, restlessness, aggressive behavior, concentration problems, altered reactions, depression, confusion, speech disorders (sometimes, complete loss of speech), visual disturbances, tremors, paralysis, tingling sensations (paresthesias), numbness and tingling sensations in the mouth area, dizziness, loss of self-control, inability to take care of oneself, convulsions, and loss of consciousness.
The first warning signs of hypoglycemia ("warning symptoms") may change, weaken, or be absent if:
In this case, you may develop severe hypoglycemia (and even lose consciousness) before you realize the problem. Always be familiar with your warning symptoms. If necessary, more frequent blood sugar testing can help identify mild hypoglycemic episodes that might otherwise go unnoticed. If you are not sure you can recognize your warning symptoms, avoid situations (such as driving a car) that could put you or others at risk due to hypoglycemia.
What to do if you experience hypoglycemia?
Tell your family, friends, and people close to you the following:
If you are unable to swallow or lose consciousness, you will need an injection of glucose or glucagon (a medication that increases blood sugar levels). These injections are justified even if you are not sure you have hypoglycemia.
It is recommended to check your blood sugar level immediately after ingesting glucose to confirm that you actually have hypoglycemia.
THE FOLLOWING INFORMATION IS INTENDED ONLY FOR HEALTHCARE PROFESSIONALS:
Apidra can be administered intravenously, and this should be done by healthcare professionals.
Instructions for Intravenous Administration
Apidra should be used at a concentration of 1 Unit/ml of insulin glulisine in infusion systems with a sodium chloride 9 mg/ml (0.9%) infusion solution with or without 40 mmol/l of potassium chloride using co-extruded polyolefin/polyamide plastic infusion bags with a dedicated infusion line. Insulin glulisine for intravenous use at a concentration of 1 Unit/ml is stable at room temperature for 48 hours.
After dilution for intravenous use, the solution should be visually inspected for particles before administration. It should only be used if the solution is clear and colorless; it should not be used if it is cloudy or contains visible particles.
Apidra has been shown to be incompatible with 5% glucose solution and Ringer's solution, and therefore should not be used with these solutions. The use of other solutions has not been studied.